drugset / Trial / NCT04419649
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
Non-randomizedSequentialOpen-labelTreatment
Summary
The main aim of this study is to learn how safe elritercept is and how well adults with anemia associated with lower-risk MDS tolerate treatment with different doses of elritercept. Other aims are to learn how safe elritercept is by looking at how many participants have MDS that worsens during the study and learn about the effects of elritercept on anemia linked to MDS. The study will also look to learn how elritercept affects the production of healthy RBCs.
Timeline
- Start
- 2020-08-19
- Primary completion
- 2029-10-30
- Completion
- 2031-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Elritercept | Protein / enzyme biologic | 0.75 mg/kg | Subcutaneous |
| Subject | Elritercept | Protein / enzyme biologic | 1.5 mg/kg | Subcutaneous |
| Subject | Elritercept | Protein / enzyme biologic | 2.5 mg/kg | Subcutaneous |
| Subject | Elritercept | Protein / enzyme biologic | 3.75 mg/kg | Subcutaneous |
| Subject | Elritercept | Protein / enzyme biologic | 5 mg/kg | Subcutaneous |